Cover Not all injectable peptides are equal. The evidence behind each compound varies (Photo: Getty Images)
Not all injectable peptides are equal. The evidence behind each compound varies (Photo: Getty Images)
1 / 1
From FDA-approved medicines to unregulated research chemicals, peptides are being sold and marketed as a single category. The gap between them is wider than most clinic brochures suggest
Peptides have become one of the most discussed—and most loosely defined—categories in longevity. These are short chains of amino acids, and some peptide hormones help regulate appetite, growth hormone release and tissue repair.
The logic of synthetic peptide therapy is straightforward: if you can identify what signal a peptide sends and replicate it, you might prompt the body to do something specific. Some of this has produced transformative medicine—insulin being the oldest example. What started as a precise medical tool for specific diseases has moved into the mainstream, appearing on clinic menus, social media feeds, and in conversations about recovery, skin and cellular health.
Read more: Longevity’s most-used words, decoded
The category is not what it seems
Peptide therapy has become an umbrella term covering two almost entirely different things. On one side are regulated medicines such as semaglutide, a GLP-1 receptor agonist sold under brands including Ozempic and Wegovy, and tirzepatide, a GIP/GLP-1 receptor agonist sold under brands including Mounjaro and Zepbound. The evidence base for this class is among the strongest in modern metabolic medicine.
On the other: a range of synthetic compounds tested primarily in animals, administered off-label through wellness clinics and compounding pharmacies to otherwise healthy people, on the basis of promising preclinical data and theoretical mechanisms that have not yet been established in human trials.
The word peptide has become a credibility shortcut, borrowing the scientific authority of the GLP-1 drugs and applying it to a much broader category of molecules sold online, often without prescription or clinical oversight.
Read more: Are skincare and beauty lines backed by doctors better than celebrity brands?
What the evidence supports
Above Oral peptides come in multiple forms including powders and pills (Photo: Getty Images)
Oral peptides come in multiple forms including powders and pills (Photo: Getty Images)
1 / 1
Semaglutide and tirzepatide are FDA and EMA approved in the US and EU for type 2 diabetes and specific formulations are approved for obesity. Large-scale randomised trials have established significant weight loss results and cardiovascular risk reduction.
The 2023 Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial published in the New England Journal of Medicine found that semaglutide reduced major cardiovascular events in people with obesity who did not have diabetes. This finding has excited researchers about the drug class’s broader metabolic and anti-inflammatory potential. These are prescription medicines with defined indications, known side-effect profiles and contraindications. They are not casual wellness upgrades.
Oral collagen peptide supplements have more modest but reasonable evidence behind them. A 2024 meta-analysis found improvements in fat-free mass, tendon morphology, muscle architecture, maximal strength and some recovery outcomes when collagen peptides were combined with training. Several randomised trials also showed skin hydration benefits. However, the effects are incremental and exercise-dependent; meaningful, but a long way from the transformations implied by most supplement marketing.
See also: Natural supplements are all the rage. But are they actually good for us?
Where the evidence thins
Beyond those categories, the evidence thins rapidly. BPC-157 and TB-500, or known as the “Wolverine stack”, are typically marketed for recovery, gut health and injury repair. Unlike semaglutide, they have extensive animal research and very limited rigorous human trial data. Studies in humans have largely been small, uncontrolled and without placebo comparisons. In 2023, the FDA raised concerns that BPC-157 and TB-500 could be risky or poorly made when mixed into compounded medicines.
Growth hormone-stimulating peptides sit in similar territory. Some peptides can raise growth hormone levels in specific clinical settings, but evidence for meaningful benefit in healthy adults is limited. There is also a theoretical cancer‑promotion risk, and they are banned in competitive sport.
Above Growth hormone-stimulating peptides have limited human trial data and are banned in competitive sport by the World Anti-Doping Agency (Photo: Getty Images)
Growth hormone-stimulating peptides have limited human trial data and are banned in competitive sport by the World Anti-Doping Agency (Photo: Getty Images)
1 / 1
A further group of compounds is marketed in longevity clinics as tools that target the biology of ageing at a cellular level. The science behind the concept is legitimate and actively researched. The specific compounds being administered through wellness channels are a different matter. In almost every case, they have been tested only in animals, not in humans.
The FDA estimates that between 90 and 95 per cent of drug candidates that appear promising in animal studies fail in human trials. That is not a reason to dismiss the research direction. It is a reason not to treat it as a clinical option.
Before you book
If a clinician is recommending a peptide, the questions worth asking are:
- Is this compound approved for this indication in this country?
- What human trial evidence specifically supports it for my situation—not animal data, not theoretical mechanism?
- What are the known contraindications relative to my medical history?
- Where is it sourced, and how is quality assured?
When it comes to peptides, it’s important to resist conflation. The GLP-1 story has significant clinical science, but much of the rest of the peptide market remains, for now, an interesting hypothesis and should be approached as one.
Topics
Work
Based in Singapore, Valerie Lim is the digital editor for Tatler Power and Purpose, Tatler Asia’s dynamic platform spotlighting industry leaders across the region. Valerie leads the charge in shaping the platform’s digital presence, from overseeing and producing website content to curating social media strategies.
With a finger on the pulse of the region, she keeps an eye out for news and trends in business, innovation and leadership, ensuring the brand stays ahead of the curve in delivering stories that inspire and inform its community of changemakers.
About
Prior to this role, she worked in marketing and communications. She considers herself Singaporean at heart and international by passion. You may recognise her from her 15 minutes of fame when she was crowned Miss Universe Singapore 2011. When she is not at her desk, you can find her in the gym or at a yoga studio.
Connect with her via Instagram @msvalerielim, LinkedIn or send press materials, and media invites to valerie.lim@tatlerasia.com
